Painchek Ltd · ASX:PCK
Painchek — Shareholder Meeting (November 2023)
23 slides from Painchek's shareholder meeting presentation, Nov 22, 2023
Slide 1: 2023 Annual General Meeting – CEO Presentation
ASX ANNOUNCEMENT 22 November 2023 2023 Annual General Meeting – CEO Presentation PainChek® Ltd (ASX: PCK) (“PainChek®” or “the Company”), developer of the world’s first smart phone- based pain assessment and monitoring application, is pleased to provide the attached slides ahead of the presentation
Slide 2: PainChek Shared Care Program
The PainChek® Shared Care Program is a PainChek® licensing model which enables a professional carer to share their resident or patient data securely with other healthcare professionals or designated homebased family carers for ongoing pain assessments or clinical data review. To find out more, visit
Slide 3: AGM November 2023
For personal use only AGM November 2023 PHILIP DAFFAS, CEO & MD PAINCHEK LTD | ASX:PCK 1 |
Slide 4: Our purpose is to give a voice to people who cannot verbalise pain
For personal use only Our purpose is to give a voice to people who cannot reliably verbalise their pain
Slide 5: The PainChek Universal App: quick and easy operation
THE PAINCHEK® UNIVERSAL APP: QUICK AND EASY OPERATION A medical device in your pocket - CE Mark Digitalized System: For personal use only - ISO 27001 - GDPR • 42 digital test points across 6 domains compliant • generates overall pain severity score • no pain, mild, moderate or severe Medical App on
Slide 6: The growing global market need for PainChek
THE GROWING GLOBAL MARKET NEED FOR PAINCHEK For personal use only 400M pre-verbal children1 25-42% of hospital beds occupied by people with dementia4,5 57M people living with dementia >150M expected by 20502,3 1. Ecology Communications Group. www.ecology.com/birth-death-rates 4. Tsai, I. P., Jeong,
Slide 7: PainChek across the dementia journey
PAINCHEK® ACROSS THE DEMENTIA JOURNEY For personal use only HCP Carers HCO Physio GP Physio GP/Spec GP Care Environment Family managed Home Professional Home Care Long Term Care Carer Family Family + Health Health Care Care Professional Professionals Dementia Stage Onset Dementia Moderate Dementia M
Slide 8: PainChek around the world and across Australia
PAINCHEK AROUND THE WORLD…..AND ACROSS AUSTRALIA 77,000 LICENCES, 1200 AGED CARE FACILITIES ACROSS 3 CONTINENTS Canada For personal use only • Initial RAC sales now in European Union (EU) place and implemented • Targeting RAC beds and • Exploring additional home care dementia Aged Care and Home pati
Slide 9: PainChek's partners: access to 1,500,000 aged care beds
PAINCHEK’S PARTNERS: ACCESS TO 1,500,000 AGED CARE BEDS AND A PATHWAY TO ACCELERATED GLOBAL GROWTH PainChek integrates and works with aged care management and medication management systems covering more than 1,500,000 For personal use only aged care beds across ANZ, UK and North America These integr
Slide 10: PainChek Analytics
PAINCHEK ANALYTICS DRIVING TOWARDS PERSONALISED PAIN MANAGEMENT PainChek® Analytics provides actionable insights from your PainChek® pain assessment data to personalize pain assessment, reduce clinical risk, and ensure pain is identified early, so allowing carers to focus on providing care. For pers
Slide 11: PainChek across Australia
PAINCHEK ACROSS AUSTRALIA AGED CARE’s MOST POPULAR DIGITAL CLINICAL TOOL Aged Care • PainChek commercial licences cover more than 57,000 beds and 800 aged care homes, approx. 30% of total AU market and growing with a For personal use only current retention rate of 85%. • UCQ becomes PCK’s largest cl
Slide 12: PainChek's growing UK footprint
PAINCHEK’S GROWING UK FOOTPRINT • PainChek commercial licences in UK aged care now cover ~21,500 bed licences, 400+ care homes across 93 organisations • New clients in October include BUPA UK – initial 500 bed license pilot For personal use only agreement across 8 homes agreement with the potential
Slide 13: St Michael's Health Group – PainChek's first Canadian commercial client
ST MICHAEL'S HEALTH GROUP- P A I N C H E K ’ s 1 ST C A N A D I A N C O M M E R C I A L C L I E N T “Our search for the latest advancements in For personal use only FEEDBACK aged care led us to implement PainChek at St. Michael’s Health Group. We consider ourselves lucky that we came across PainChek
Slide 14: Scottish Care Inspectorate PainChek – 1st phase outcomes
S C O T T I S H C A R E I N S P E C T O R A T E P A I N C H E K - 1 st P H A S E O U T C O M E S "We welcome the use of innovation and technology to help support people to experience the best possible care.” “This device should enable more appropriate use of medication and improved quality of life f
Slide 15: PainChek features on national Scottish News at Six
PainChek features on national Scottish News at Six As part of its Quality For personal use only Improvement Plan, the Scottish Care inspectorate has received funding from the central government to improve outcomes for residents across 15 care homes, with the view to potentially implement the technol
Slide 16: Market partnerships and drivers for USA & Canada
MARKET PARTNERSHIPS AND DRIVERS FOR USA & CANADA For personal use only PAINCHEK IS TARGETING FDA DE NOVO CLEARANCE AND US LAUNCH IN 2024 NORTH AMERICAN LONG TERM CARE PointClickCare: PainChek integrated with MARKET OPPORTUNITY PointClickCare leading long term care provider in USA & Canada – providin
Slide 17: PainChek well positioned to exploit large global market opportunities
PAINCHEK WELL POSITIONED TO EXPLOIT LARGE GLOBAL MARKET OPPORTUNITES For personal use only AGED CARE MARKET HOME CARE INFANT MARKET HOSPITAL MARKET 6 MILLION BEDS 1 UP TO 10X AGED 400M PRE-VERBAL ~$1Bn ANNUALLY 4 CARE MARKET 2 CHILDREN & - 150M ANNUALLY TO $300M ANNUAL FIRST TIME PARENTS 3 ARR 2 1.
Slide 18: PainChek Infant
PAINCHEK® INFANT Making Infant Pain Visible…and Audible For personal use only 1. 2. 3. 4. 5. 1 Parent or Caregiver PainChek® Infant Parent or Caregiver PainChek® Infant Facial Parent or Caregiver uses hears an Vocalisation technology intervenes and treats technology measures PainChek® Infant to meas
Slide 19: PainChek upcoming catalysts
PAINCHEK UPCOMING CATALYSTS For personal use only Continued acceleration of sales and ARR Complete FDA studies to obtain US growth within RAC, Retirement and Home FDA De Novo clearance in Q2 CY 24 Care setting in ANZ, UK, Canada and new EU opportunities in CY 24 Enter global hospital market sector L
Slide 20: Corporate summary
CORPORATE SUMMARY Top shareholders % For personal use only Financial information Peters Investments Proprietary Ltd 8.4% Share price (21 November 2023) A$0.045 Founders 5.4% Shares on issue 1,406.3m Board & key staff 3.8% Market capitalisation A$63.3m Cash (30 September 2023) A$3.7m Unlisted options
Slide 21: The Team
THE TEAM For personal use only Philip Daffas Prof. Jeff Hughes Andrew Hoggan Iain McAdam CEO & Managing Chief Scientific Head of Operations CFO Director, MBA, BSc Officer PhD, MPS Philip is a highly accomplished Jeff is a professor in the Andy is a Psychologist, Iain has over 20 years finance & glob
Slide 22: The Board
THE BOARD For personal use only John Murray Philip Daffas Ross Harricks Adam Davey Cynthia Payne Non-Exec Chair CEO & Managing Non-Exec Director Non-Exec Director Non-Exec Director Director 25 years in tech & Philip is a highly Senior global medical Corporate finance 30 years executive Venture Capit
Slide 23: AGM November 2023
For personal use only AGM November 2023 PHILIP DAFFAS, CEO & MD PAINCHEK LTD | ASX:PCK 21 |